Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2012
Date: 2014-10-09
Institutions: Standing Committee of the EFTA States
Subjects: EFTA countries, free movement of goods, market approval, medicinal product








C_2014356EN.01002201.xml










9.10.2014   


EN


Official Journal of the European Union


C 356/22





Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2012
2014/C 356/07

Subcommittee I on the free movement of goods


To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January-30 June 2012, at their meeting on 15 July 2013:







Annex I



List of new marketing authorisations





Annex II



List of renewed marketing authorisations





Annex III



List of extended marketing authorisations





Annex IV



List of withdrawn marketing authorisations





Annex V



List of suspended marketing authorisations






ANNEX I
List of new marketing authorisations
The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January-30 June 2012:








EU-Number


Product


Country


Date of authorisation




EU/1/11/711/001-030


Matever


Norway


1.6.2012




EU/1/11/712/001-028


Levetiracetam Accord


Norway


13.4.2012




EU/1/11/713/001-040


Levetiracetam Actavis


Norway


16.4.2012




EU/1/11/715/001-002


Plenadren


Iceland


23.4.2012




EU/1/11/721/001-021


Paglitaz


Norway


13.4.2012




EU/1/11/721/001-021


Paglitaz


Iceland


17.4.2012




EU/1/11/722/001-030


Pioglitazone Accord


Norway


11.4.2012




EU/1/11/722/001-030


Pioglitazon Accord


Liechtenstein


30.4.2012




EU/1/11/722/001-030


Pioglitazone Accord


Iceland


20.4.2012




EU/1/11/723/001-021


Pioglitazone Krka


Norway


23.5.2012




EU/1/11/723/001-021


Pioglitazone Krka


Iceland


20.4.2012




EU/1/11/727/001


Mercatopurine Nova lab.


Norway


19.4.2012




EU/1/11/727/001


Mercaptopurine Nova Laboratories


Iceland


3.4.2012




EU/1/11/727/001


Mercatopurine Nova Laboratories


Liechtenstein


30.4.2012




EU/1/11/729/001-006


Onduarp


Norway


8.5.2012




EU/1/11/730/001-060


Rasitrio


Iceland


3.2.2012




EU/1/11/738/001-003


Levetiracetam Actavis Gr.


Norway


1.3.2012




EU/1/11/739/001-008


Dasselta


Norway


16.1.2012




EU/1/11/740/001


Ameluz


Iceland


5.1.2012




EU/1/11/740/001


Ameluz


Norway


16.1.2012




EU/1/11/741/001


Levetiracetam SUN


Norway


27.1.2012




EU/1/11/741/001


Levetiracetam Sun


Iceland


9.1.2012




EU/1/11/742/001-010


Efavirenz Teva


Norway


13.2.2012




EU/1/11/742/001-010


Efavirenz Teva


Iceland


24.1.2012




EU/1/11/742/001-010


Efavirenz Teva


Liechtenstein


29.2.2012




EU/1/11/743/001-015


Repaglinide Accord


Norway


13.2.2012




EU/1/11/743/001-015


Repaglinide Accord


Iceland


19.1.2012




EU/1/11/743/001-015


Repaglinide Accord


Liechtenstein


29.2.2012




EU/1/11/744/001-002


Topotecan Eagle


Iceland


22.1.2012




EU/1/11/744/001-002


Topotecan Eagle


Liechtenstein


29.2.2012




EU/1/11/745/001-009


Desloratadine Actavis


Iceland


3.2.2012




EU/1/11/745/001-009


Desloratadine Actavis


Norway


13.2.2012




EU/1/11/746/001-012


Desloratadine ratiopharm


Norway


13.2.2012




EU/1/11/746/001-012


Desloratadine ratiopharm


Iceland


3.2.2012




EU/1/11/746/001-012


Desloratadine ratiopharm


Liechtenstein


29.2.2012




EU/1/11/747/001


Colobreathe


Iceland


29.2.2012




EU/1/11/747/001


Colobreathe


Liechtenstein


29.2.2012




EU/1/11/748/001-006


Docetaxel Mylan


Iceland


7.2.2012




EU/1/11/748/001-006


Docetaxel Mylan


Liechtenstein


29.2.2012




EU/1/11/749/001-002


Caprelsa


Liechtenstein


30.4.2012




EU/1/11/749/001-003


Caprelsa


Iceland


9.3.2012




EU/1/11/749/001-002


Caprelsa


Norway


13.3.2012




EU/1/12/750/001


Esmya


Norway


30.3.2012




EU/1/12/750/001


Esmya


Iceland


14.3.2012




EU/1/12/750/001


Esmya


Liechtenstein


30.4.2012




EU/1/12/751/001


Zelboraf


Norway


14.3.2012




EU/1/12/751/001


Zelboraf


Iceland


7.3.2012




EU/1/12/751/001


Zelboraf


Liechtenstein


29.2.2012




EU/1/12/752/001


Vepacel


Norway


1.3.2012




EU/1/12/752/001


Vepacel


Iceland


9.3.2012




EU/1/12/752/001


Vepacel


Liechtenstein


29.2.2012




EU/1/12/753/001-012


Signifor


Norway


10.5.2012




EU/1/12/753/001-012


Signifor


Iceland


24.5.2012




EU/1/12/753/001-012


Signifor


Liechtenstein


30.6.2012




EU/1/12/754/001-021


Sepioglin


Norway


10.4.2012




EU/1/12/754/001-021


Sepioglin


Iceland


3.4.2012




EU/1/12/754/001-021


Sepioglin


Liechtenstein


30.4.2012




EU/1/12/755/001-027


Pioglitazone Actavis


Norway


13.4.2012




EU/1/12/755/001-027


Pioglitazone Actavis


Iceland


30.4.2012




EU/1/12/756/001-027


Glidipion (ex Ogliton)


Norway


13.4.2012




EU/1/12/756/001-027


Pioglitazone Actavis Group


Iceland


13.4.2012




EU/1/12/756/001-027


Pioglitazone Actavis Group


Liechtenstein


30.4.2012




EU/1/12/757/001-030


Pioglitazone Teva


Norway


11.4.2012




EU/1/12/757/001-030


Pioglitazone Teva


Iceland


23.4.2012




EU/1/12/758/001-030


Pioglitazone Teva Pharma


Norway


17.4.2012




EU/1/12/758/001-030


Pioglitazone Teva Pharma


Iceland


25.4.2012




EU/1/12/759/001-003


Zoledronic acid Actavis


Norway


8.5.2012




EU/1/12/759/001-003


Zoledronic acid Actavis


Iceland


16.5.2012




EU/1/12/759/001-003


Zoledronsäure Actavis


Liechtenstein


30.4.2012




EU/1/12/760/001-002


Bronchitol


Norway


18.5.2012




EU/1/12/760/001-002


Bronchitol


Iceland


9.5.2012




EU/1/12/761/001-002


Capecitabine Teva


Norway


30.5.2012




EU/1/12/761/001-002


Capecitabine Teva


Iceland


20.5.2012




EU/1/12/761/001-002


Capecitabin Teva


Liechtenstein


30.4.2012




EU/1/12/762/001-018


Capecitabine Accord


Iceland


20.5.2012




EU/1/12/762/001-018


Capecitabin Accord


Liechtenstein


30.4.2012




EU/1/12/763/001-018


Capecitabine Krka


Iceland


16.5.2012




EU/1/12/763/001-018


Capecitabin Krka


Liechtenstein


30.4.2012




EU/1/12/763/001-018


Capecitabine Krka


Norway


14.6.2012




EU/1/12/764/001


Pixuvri


Norway


14.6.2012




EU/1/12/764/001


Pixuvri


Iceland


29.5.2012




EU/1/12/764/001


Pixuvri


Liechtenstein


30.6.2012




EU/1/12/765/001-004


Sabervel


Iceland


9.5.2012




EU/1/12/765/001-006


Sabervel


Norway


8.5.2012




EU/1/12/765/001-006


Sabervel


Liechtenstein


30.4.2012




EU/1/12/766/001


Sancuso


Norway


10.5.2012




EU/1/12/766/001


Sancuso


Iceland


20.5.2012




EU/1/12/766/001


Sancuso


Liechtenstein


30.6.2012




EU/1/12/767/001-007


Nimenrix


Norway


1.5.2012




EU/1/12/767/001-007


Nimenrix


Iceland


16.5.2012




EU/1/12/768/001


Riluzole Zentiva


Iceland


25.5.2012




EU/1/12/768/001


Riluzol Zentiva


Liechtenstein


30.6.2012




EU/1/12/769/001-003


Docetaxel Accord


Iceland


12.6.2012




EU/1/12/769/001-003


Docetaxel Accord


Liechtenstein


30.6.2012




EU/1/12/770/001-004


Docetaxel Kabi


Norway


19.6.2012




EU/1/12/770/001-004


Docetaxel Kabi


Iceland


13.6.2012




EU/1/12/770/001-004


Docetaxel Kabi


Liechtenstein


30.6.2012




EU/2/11/134/001-014


Inflacam


Norway


6.1.2012




EU/2/11/135/001-003


Panacur AquaSol


Norway


10.2.2012




EU/2/11/136/001


Truscient


Norway


6.1.2012




EU/2/11/136/001


TruScient


Iceland


12.1.2012




EU/2/11/137/001-015


Activyl Tick Plus


Norway


13.2.2012




EU/2/11/137/001-015


Activyl Tick Plus


Iceland


25.1.2012




EU/2/11/137/001-015


Activyl Tick Plus


Liechtenstein


29.2.2012




EU/2/12/138/001-003


RevitaCAM


Iceland


14.3.2012




EU/2/12/139/001-003


Zulvac 1 + 8 Bovis


Norway


3.4.2012




EU/2/12/139/001-003


Zulvac 1 + 8 Bovis


Iceland


4.4.2012




EU/2/12/139/001-003


Zulvac 1 + 8 Bovis


Liechtenstein


30.4.2012







ANNEX II
List of renewed marketing authorisations
The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January-30 June 2012:








EU-Number


Product


Country


Date of authorisation




EU/1/01/197/001-005


Foscan


Iceland


14.5.2012




EU/1/01/200/001-002


Viread


Norway


6.1.2012




EU/1/01/200/001-002


Viread


Iceland


5.1.2012




EU/1/02/209/001-008


Dynastat


Norway


8.3.2012




EU/1/02/209/001-008


Dynastat


Iceland


7.2.2012




EU/1/02/209/001-008


Dynastat


Liechtenstein


29.2.2012




EU/1/02/212/001-026


Vfend


Norway


6.3.2012




EU/1/02/212/001-026


Vfend


Iceland


14.3.2012




EU/1/02/212/001-026


Vfend


Liechtenstein


30.4.2012




EU/1/02/216/001-002


Invanz


Norway


19.1.2012




EU/1/02/216/001-002


Invanz


Iceland


20.1.2012




EU/1/02/216/001-002


Invanz


Liechtenstein


29.2.2012




EU/1/02/220/001-006


Tracleer


Norway


8.5.2012




EU/1/02/220/001-006


Tracleer


Iceland


20.5.2012




EU/1/02/220/001-006


Tracleer


Liechtenstein


30.4.2012




EU/1/02/222/001-005


Tamiflu


Norway


8.3.2012




EU/1/02/222/001-005


Tamiflu


Iceland


19.6.2012




EU/1/02/222/001-005


Tamiflu


Liechtenstein


30.6.2012




EU/1/06/334/001-005


Evoltra


Liechtenstein


30.4.2012




EU/1/06/347/001-008


Sutent


Liechtenstein


29.2.2012




EU/1/06/366/005-022


Tandemact


Norway


11.4.2012




EU/1/06/366/005-022


Tandemact


Iceland


22.3.2012




EU/1/06/366/005-022


Tandemact


Liechtenstein


30.4.2012




EU/1/06/367/001-012


Diacomit


Norway


6.3.2012




EU/1/06/367/001-012


Diacomit


Iceland


7.2.2012




EU/1/06/367/001-012


Diacomit


Liechtenstein


29.2.2012




EU/1/06/370/001-039


Exforge


Norway


16.1.2012




EU/1/06/370/001-039


EXFORGE


Iceland


3.2.2012




EU/1/06/371/001-039


Dafiro


Iceland


8.2.2012




EU/1/06/371/001-039


Dafiro


Liechtenstein


29.2.2012




EU/1/06/372/001-039


Copalia


Norway


11.1.2012




EU/1/06/373/001-039


Imprida


Norway


16.1.2012




EU/1/06/373/001-039


Imprida


Iceland


6.2.2012




EU/1/06/374/001


Lucentis


Norway


17.1.2012




EU/1/06/374/001


Lucentis


Iceland


12.1.2012




EU/1/06/376/001-033


Irbesartan Zentiva (ex-Winthrop)


Norway


14.2.2012




EU/1/06/376/001-033


Irbesartan Zentiva


Iceland


7.2.2012




EU/1/06/376/001-033


Irbesartan Winthrop


Liechtenstein


29.2.2012




EU/1/06/377/001-028


Irbesartan HCT Zentiva (ex-Winthrop)


Norway


16.4.2012




EU/1/06/377/001-028


Irbesartan HCT Zentiva


Iceland


22.3.2012




EU/1/06/377/001-028


Irbesartan HCT


Liechtenstein


30.4.2012




EU/1/06/378/001-017


Inovelon


Norway


6.3.2012




EU/1/06/378/001-017


Inovelon


Iceland


24.1.2012




EU/1/06/378/001-017


Inovelon


Liechtenstein


29.2.2012




EU/1/06/379/001


Cystadane


Iceland


9.3.2012




EU/1/06/379/001


Cystadane


Liechtenstein


29.2.2012




EU/1/06/386/001-015, 020-024, 029-033, 038-042, 047-051, 056-057, 088102, 113-150, 163-168


Insulin Human Winthrop


Norway


6.1.2012




EU/1/07/382/001-018


Xelevia


Norway


14.2.2012




EU/1/07/382/001-018


Xelevia


Iceland


6.2.2012




EU/1/07/382/001-018


Xelevia


Liechtenstein


29.2.2012




EU/1/07/383/001-018


Januvia


Norway


26.3.2012




EU/1/07/383/001-018


Januvia


Iceland


11.5.2012




EU/1/07/383/001-018


Januvia


Liechtenstein


30.4.2012




EU/1/07/384/003-005


Docetaxel Winthrop


Norway


10.4.2012




EU/1/07/384/003-005


Docetaxel Winthrop


Iceland


23.3.2012




EU/1/07/384/003-005


Docetaxel Winthrop


Liechtenstein


30.4.2012




EU/1/07/386/001-018


Toviaz


Norway


11.4.2012




EU/1/07/386/001-018


Toviaz


Iceland


10.4.2012




EU/1/07/386/001-018


Toviaz


Liechtenstein


30.4.2012




EU/1/07/387/001-026


Advagraf


Norway


2.5.2012




EU/1/07/387/001-026


Advagraf


Iceland


9.5.2012




EU/1/07/387/001-026


Advagraf


Liechtenstein


30.4.2012




EU/1/07/388/001-003


Sebivo


Norway


8.5.2012




EU/1/07/388/001-003


Sebivo


Iceland


16.5.2012




EU/1/07/388/001-003


Sebivo


Liechtenstein


30.4.2012




EU/1/07/389/001-003


Orencia


Norway


10.4.2012




EU/1/07/389/001-003


Orencia


Iceland


10.4.2012




EU/1/07/389/001-003


Orencia


Liechtenstein


30.4.2012




EU/1/07/390/001-004


Altargo


Norway


8.5.2012




EU/1/07/390/001-004


Altargo


Iceland


16.5.2012




EU/1/07/390/001-004


Altargo


Liechtenstein


30.4.2012




EU/1/07/391/001-004


Revlimid


Norway


3.5.2012




EU/1/07/391/001-004


Revlimid


Iceland


9.5.2012




EU/1/07/391/001-004


Revlimid


Liechtenstein


30.4.2012




EU/1/07/392/001-003


Circadin


Norway


16.5.2012




EU/1/07/392/001-003


Circadin


Iceland


10.5.2012




EU/1/07/392/001-003


Circadin


Liechtenstein


30.6.2012




EU/1/07/394/001-009


Optaflu


Norway


20.6.2012




EU/1/07/395/001-095


Invega


Liechtenstein


30.6.2012




EU/1/07/396/001-003


Pergoveris


Iceland


20.6.2012




EU/1/07/396/001-003


Pergoveris


Liechtenstein


30.6.2012




EU/1/07/398/001-014


Optimark


Norway


27.6.2012




EU/1/07/399/001-006


Aerinaze


Norway


18.6.2012




EU/1/07/399/001-006


Aerinaze


Liechtenstein


30.6.2012




EU/1/07/399/001-006


Aerinaze


Iceland


20.6.2012




EU/1/07/400/008-013, 017-024


Mircera


Iceland


7.6.2012




EU/1/07/400/008-013, 017-024


Mircera


Norway


14.6.2012




EU/1/07/400/017-024


Mircera


Liechtenstein


30.6.2012




EU/1/07/401/007-016


alli


Norway


29.6.2012




EU/1/07/412/001-052


Abseamed


Liechtenstein


30.6.2012




EU/1/07/423/001-003


Vectibix


Norway


19.3.2012




EU/1/07/423/001-003


Vectibix


Iceland


9.3.2012




EU/1/07/440/001-003


Tyverb


Liechtenstein


30.4.2012




EU/1/07/440/001-006


Tyverb


Norway


2.5.2012




EU/1/07/440/001-006


Tyverb


Iceland


11.5.2012




EU/1/10/625/001&003


Arzerra


Iceland


17.2.2012




EU/1/10/625/001&003


Arzerra


Norway


18.5.2012




EU/1/10/628/001-004


Votrient


Norway


19.6.2012




EU/1/10/628/001-004


Votrient


Iceland


13.6.2012




EU/1/11/699/001-004


Fampyra


Norway


19.6.2012




EU/1/11/699/001-004


Fampyra


Iceland


13.6.2012




EU/1/11/699/001-004


Fampyra


Liechtenstein


30.6.2012




EU/2/05/053/001-003


Naxcel


Norway


14.2.2012




EU/2/06/068/001-004


Ypozane


Norway


13.2.2012




EU/2/06/068/001-004


Ypozane


Iceland


18.1.2012




EU/2/06/068/001-004


Ypozane


Liechtenstein


30.4.2012




EU/2/06/070/001-008


Meloxidyl


Iceland


13.1.2012




EU/2/07/071/001-003


SLENTROL


Iceland


7.5.2012




EU/2/07/071/001-003


Slentrol


Liechtenstein


30.4.2012




EU/2/07/072/001-004


Suprelorin


Iceland


21.6.2012




EU/2/07/074/001-006


Prilactone


Iceland


13.6.2012




EU/2/07/075/001-004


Circovac


Liechtenstein


30.6.2012




EU/2/07/075/001-004


Circovac


Iceland


4.6.2012







ANNEX III
List of extended marketing authorisations
The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January-30 June 2012:








EU-Number


Product


Country


Date of authorisation




EU/1/00/141/002


Myocet


Liechtenstein


30.4.2012




EU/1/02/222/05


Tamiflu


Iceland


6.2.2012




EU/1/03/262/009-010


Emend


Norway


5.1.2012




EU/1/03/262/009-010


Emend


Iceland


3.2.2012




EU/1/03/271/007-010


Advate


Norway


23.1.2012




EU/1/03/271/007-010


Advate


Iceland


17.1.2012




EU/1/05/318/003


Revatio


Norway


13.4.2012




EU/1/05/318/003


Revatio


Iceland


17.4.2012




EU/1/05/318/003


Revatio


Liechtenstein


30.4.2012




EU/1/06/339/003


Preotact


Liechtenstein


30.6.2012




EU/1/08/465/021


Clopidogrel Zentiva


Liechtenstein


30.6.2012




EU/1/08/468/002


INTELENCE


Iceland


3.1.2012




EU/1/08/470/018-019


Vimpat


Norway


14.3.2012




EU/1/08/470/018-019


Vimpat


Iceland


14.3.2012




EU/1/08/470/018-019


Vimpat


Liechtenstein


30.4.2012




EU/1/08/472/011-021


Xarelto


Norway


4.1.2012




EU/1/08/475/035-060


Olanzapin Mylan


Liechtenstein


29.2.2012




EU/1/09/536/003-004


Topotecan Actavis


Liechtenstein


30.4.2012




EU/1/09/551/013-027


Vizarsin


Iceland


7.6.2012




EU/1/09/551/013-027


Vizarsin


Liechtenstein


30.6.2012




EU/1/09/571/002


Pandemic influenza vaccine H5N1 Baxter


Liechtenstein


30.4.2012




EU/1/11/667/004


Esbriet


Liechtenstein


30.4.2012




EU/1/11/699/003-004


Fampyra


Liechtenstein


30.4.2012




EU/1/11/701/029-032


Levetiracetam Teva


Liechtenstein


30.6.2012




EU/1/11/703/003


Xgeva


Liechtenstein


29.2.2012




EU/1/11/704/002


Victrelis


Liechtenstein


30.4.2012




EU/1/11/720/002


Incivo


Liechtenstein


30.6.2012




EU/1/97/044/009


Tasmar


Liechtenstein


30.4.2012




EU/2/07/078/015-017


Rheumocam


Norway


13.2.2012




EU/2/07/078/015-017


Rheumocam


Iceland


7.2.2012




EU/2/07/078/015-017


Rheumocam


Liechtenstein


29.2.2012




EU/2/08/085/002-006


Easotic


Liechtenstein


30.4.2012




EU/2/08/090/027


Loxicom


Liechtenstein


30.6.2012




EU/2/10/114/003


Hiprabovis IBR Marker Live


Liechtenstein


29.2.2012




EU/2/97/004/049


Metacam


Liechtenstein


29.2.2012







ANNEX IV
List of withdrawn marketing authorisations
The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January-30 June 2012:








EU-Number


Product


Country


Date of authorisation




EU/1/02/255/001-002


Xigris


Iceland


25.6.2012




EU/1/04/272/001-002


PhotoBarr


Norway


24.5.2012




EU/1/04/272/001-002


Photobarr


Iceland


20.5.2012




EU/1/04/272/001-002


PhotoBarr


Liechtenstein


30.6.2012




EU/1/06/335/001


Valtropin


Iceland


5.6.2012




EU/1/06/335/001


Valtropin


Liechtenstein


30.6.2012




EU/1/06/351/001-003


Livensa


Iceland


11.4.2012




EU/1/06/351/001-003


Livensa


Liechtenstein


30.4.2012




EU/1/06/352/001-003


Intrinsa


Liechtenstein


30.6.2012




EU/1/06/352/001-003


Intrinsa


Iceland


23.6.2012




EU/1/09/534/001-007


Clopidogrel Hexal


Iceland


2.3.2012




EU/1/09/534/001-007


Clopidgrel Hexal


Liechtenstein


29.2.2012




EU/1/09/548/001-007


Clopidogrel Acino Pharma GmbH


Iceland


2.3.2012




EU/1/09/548/001-007


Clopidgrel Acino Pharma GmbH


Liechtenstein


29.2.2012




EU/1/09/549/001-007


Clopidogrel Acino Pharma


Iceland


2.3.2012




EU/1/09/549/001-007


Clopidogrel Acino Pharma


Liechtenstein


29.2.2012




EU/1/10/630/001-002


Docefrez


Iceland


20.6.2012




EU/1/10/630/001-002


Docefrez


Liechtenstein


30.6.2012




EU/1/97/035/003-004


Refludan


Iceland


24.5.2012




EU/1/97/035/001-004


Refludan


Norway


6.6.2012




EU/1/97/035/001-004


Refludan


Liechtenstein


30.6.2012




EU/2/00/028/002-008


Zubrin


Iceland


17.4.2012




EU/2/00/028/002-008


Zubrin


Liechtenstein


30.4.2012




EU/2/03/040/001-002


Gonazon


Norway


2.4.2012




EU/2/03/040/001-002


Gonazon


Iceland


17.4.2012




EU/2/03/040/001-002


Gonazon


Liechtenstein


30.4.2012




EU/2/06/060/001-002


Poulvac FluFend H5N3 RG


Liechtenstein


30.6.2012







ANNEX V
List of suspended marketing authorisations
The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January-30 June 2012:








EU-Number


Product


Country


Date of authorisation




EU/1/06/361/001-002


Luminity


Iceland


20.6.2012




EU/1/06/361/001-002


Luminity


Liechtenstein


30.6.2012




EU/1/97/037/001


Vistide


Liechtenstein


29.2.2012




EU/1/11/705/001


Vibativ


Iceland


27.6.2012